A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

The Respiratory Centre (TRC) outpatient physiotherapy service (adults) - patient information

Description
This factsheet explains what The Respiratory Centre (TRC) outpatient physiotherapy service is, what the service offers and what to expect at your first appointment.
Url
/Media/UHS-website-2019/Patientinformation/Respiratory/The-Respiratory-Centre-TRC-outpatient-physiotherapy-service-adults-3933-PIL.pdf

Car seat challenge - patient information

Description
This factsheet explains the reasons for your baby needing a car seat challenge test and what this test involves.
Url
/Media/UHS-website-2019/Patientinformation/Childhealth/Car-seat-challenge-2939-PIL.pdf

Digital mole mapping - patient information

Description
This factsheet explains what digital mole mapping is, what it involves and what the potential benefits are.
Url
/Media/UHS-website-2019/Patientinformation/Skin/Digital-mole-mapping-2938-PIL.pdf

Your hepatitis C treatment - Zepatier® - patient information

Description
This factsheet explains how hepatitis C is treated with a medication called Zepatier®.
Url
/Media/UHS-website-2019/Patientinformation/Digestionandurinaryhealth/Hepatology/Your-hepatitis-C-treatment-Zepatier®-1595-PIL.pdf

Maviret for hepatitis C - patient information

Description
Maviret® is a combination tablet that contains two drugs (Glecaprevir 100mg and Pibrentasvir 40mg).It is used to treat Hepatitis C.
Url
/Media/UHS-website-2019/Patientinformation/Digestionandurinaryhealth/Hepatology/Maviret-for-hepatitis-C-1769-PIL.pdf

Your hepatitis C treatment (Epclusa with/without Ribavirin) - patient information

Description
You are starting a course of Epclusa® with/without ribavirin to treat your hepatitis C infection. These medications are taken in combination and should not be used alone unless informed otherwise.
Url
/Media/UHS-website-2019/Patientinformation/Digestionandurinaryhealth/Hepatology/Your-hepatitis-C-treatment-Epclusa-withwithout-Ribavirin-1621-PIL.pdf

Hepatitis C - Harvoni® with or without ribavirin - patient information

Description
Patient information factsheet Your hepatitis C treatment Harvoni® We have given you this factsheet because you have been diagnosed with hepatitis C, and have been prescribed a course of Harvoni® to treat it. This is a tablet-based treatment that aims to clear the hepatitis C virus from the body. It is very effective, but is not guaranteed to work for everyone. The team looking after you will explain whether it is likely to completely clear the virus for you. Your Harvoni® treatment will last eight weeks. How to take your tablets Harvoni® is a combined tablet, containing two drugs (sofosbuvir 400mg and ledipasvir 90mg). Take one tablet once a day with or without food. The tablet should be swallowed whole and should not be chewed or crushed as it has a bitter taste. If you miss a dose of Harvoni® and it is within 18 hours of the normal time you take it, you should take the tablet as soon as possible and then take the next dose at the usual time. If it is after 18 hours, then you should wait and take the next dose at the usual time. Do not double the dose. If you vomit within five hours of taking your dose, you should take an additional tablet. If you vomit more than five hours after taking your dose, no further dose is needed. Medications should be stored in a cool area (below 25°C) but not in a fridge. Please keep in a safe place out of the reach of children. If you accidentally take too much of your medication, contact us immediately for advice. Do not stop taking your medication unless we advise you to do so. Other medications You must tell us if you are taking any other medications, including prescription or non‑prescription medicines, recreational drugs, vitamins and herbal supplements, so we can check that these will not affect your hepatitis C treatment. Do not stop your treatment unless you have discussed it with us first. 1 www.uhs.nhs.uk Patient information factsheet Side effects Harvoni®, like all other medications, may have some side effects. Most of these are minor and will usually settle within a few days or weeks. The most commonly reported side effects are headache and fatigue (extreme tiredness). Looking after yourself during your treatment You can help to lessen any side effects of your treatment by: • drinking two litres of water a day • avoiding alcohol If you have cirrhosis, it is important that you let us know if you experience any of the following: • confusion or disorientation • swelling of your tummy or ankles • yellowing of the whites of your eyes or skin (jaundice) • coughing blood, vomiting blood or passing any blood in your stools (this can look like black tar) Contact us if you experience any of these side effects or if you develop vomiting and diarrhoea. Monitoring your progress If your virus is undetectable three months after your treatment, you will have reached ‘viral clearance’ which means that you no longer have hepatitis C. If you put yourself at risk after this, you may get the infection again. You can’t become immune to hepatitis C, but you will always have hepatitis C antibodies (virus-fighting cells) in your blood. Contraception Although the risk of passing on hepatitis C sexually is small, you should use two methods of contraception (condoms and one other method) throughout your treatment and for a further six months afterwards. This is because we are not sure what the effects of Harvoni® may be on an unborn baby. Contact us If you have any questions or concerns, please contact us. Hepatology nurse specialist team Telephone: 023 8120 4617 (Monday to Friday, 8.30am to 4.30pm) If you have any concerns outside of these hours, contact NHS 111 for advice or visit your nearest emergency department. Useful links www.britishlivertrust.org.uk www.hepctrust.org.uk 2 www.uhs.nhs.uk Patient information factsheet If you are a patient at one of our hospitals and need this document translated, or in another format such as easy read, large print, Braille or audio, please telephone 0800 484 0135 or email patientsupporthub@uhs.nhs.uk For help preparing for your visit, arranging an interpreter or accessing the hospital, please visit www.uhs.nhs.uk/additionalsupport 3 Version 2. Reviewed October 2024. Due for review October 2027. 1258 www.uhs.nhs.uk
Url
/Media/UHS-website-2019/Patientinformation/Digestionandurinaryhealth/Hepatology/Hepatitis-C-Harvoni®-with-or-without-ribavirin-1258-PIL.pdf

Form_Call for EOI BRC 2028-2035_Candidate Research Themes

Description
Expression of Interest for NIHR Southampton BRC Candidate Research Themes The NIHR Southampton BRC is running an open call inviting proposals from eligible individuals and research teams across the University Hospital Southampton – University of Southampton partnership for BRC Candidate Research theme proposals. The call offers researchers considerable flexibility to focus on any subject area or topic, providing that it falls within the BRC remit of experimental medicine. We particularly encourage ambitious and novel research proposals addressing experimental medicine that translate advances in biomedical research into benefits for patients. We are keen to encourage fresh ideas from new researchers, and all proposals are welcomed. The decisions on which themes will form part of the BRC Application will be based on a number of criteria: 1. World-class research. 2. Acknowledged excellence in your area (top 3 nationally) within the NIHR overall and specifically amongst the other BRCs. 3. Credible leader(s) who meet(s) the criteria laid out below. 4. Critical mass of aligned researchers within the UHS-UoS partnership. 5. Capacity and capability to drive innovation in the prevention, diagnosis and treatment of ill-health through early translational (experimental medicine) research. 6. Ability to translate advances in biomedical research that responds to and meets the priority research needs of the health and care system and the population. 7. Commitment to improving research culture, inclusivity, and equality across our staff, participants and PPIE contributors, including addressing the needs of diverse communities and regions with significant health and social care challenges. 8. Credible component of the NHS contribution to our nation's international competitiveness. 9. Record of partnership with patients, service users, carers and communities to improve the relevance, quality and impact of our research. 10. Capacity to attract significant investment from external funders. 11. Effective integration with other research themes. Criteria for the theme leadership role include: i) Track record of research impact that has benefited patients ii) A sustained record of excellence in research activities in their relevant subject area iii) Top 10 publications iv) National/international reputation in experimental medicine v) Demonstrable experience in improving research culture, equity, diversity and inclusions in the research workforce and developing an inclusive research portfolio that addresses health and care inequalities vi) Membership of regional or national advisory bodies, learned societies Please contact Professor Mike Grocott (mike.grocott@soton.ac.uk) to discuss this opportunity. The closing date for this application is 12.00 midday on Friday, 28th March 2025. Please return your completed application form to BRC-applications@uhs.nhs.uk, along with the proposed theme lead(s) CV (2-page IRAS format). Expressions of interest will be reviewed by a selection panel consisting of senior research leaders from UoS and UHS, including patient/public representatives. The outcome will be notified to the proposed themes' leaders and co-leaders in May 2025. Expression of Interest BRC Candidate Research Theme Title of Candidate Research Theme: Full Name of Theme Lead Position: Institution ORCID Top 10 publications Full Name of Theme Co-Lead (if applicable): Position: Institution ORCID Top 10 publications Team Members Please list all team members who will add quality and depth to the proposed Theme, including title and position (e.g. senior PIs, Clinical Research Fellows undertaking an MD/PhD and Post Doctoral Researchers, etc., area of expertise/experience and employer. Add rows below if necessary. Name: Position: Area of expertise/ experience: Employer (UHS/UoS): Please complete the information requested below: BRC Candidate Research Theme (please outline max 500 words): • Please describe theme vision, strategy and key research hypotheses and address THEME criteria 1, 2 and 5-11 above. Theme leader(s) profile (max 200 words each): • Please address THEME LEADER criteria i-vi above. • Please address THEME CO-LEADER criteria i-vi above (IF APPLICABLE) Please highlight how your theme will address innovation, inclusion and impact (500 words): • Demonstrate how the areas to be addressed and/or the approaches to be taken will drive innovation in the prevention, diagnosis and/or treatment of ill-health through early translational and experimental medicine research. • Please explain the approach to maximising research inclusion including of underrepresented groups. • Please outline how you anticipate the likely research outputs will have potential for further translation to deliver benefits for patients and the public, the health and care system and the broader economic gain. • The relevance of the expected outputs to the health of patients and the public and/or the health and care system. This should demonstrate how the research is addressing patients’ or public needs across the diversity of the population (including support for research activities being conducted in areas with the greatest disease burden in collaboration with local investigators). Partnerships/collaborations required to support the Theme (500 words): Where relevant, please provide details of how any proposed additional partners, universities or NHS organisations will contribute to the Theme. This should include details of: • The additional expertise they will bring to the Theme; • Roles that they will contribute to the Theme; • Examples of previous successful research collaborations between the additional partner(s), universities or NHS organisations, and the NHS and/or university partners. Please list current grants held (funder, amount awarded, start date and finish date) Add rows below if necessary. Funder Title of grant Amount awarded Start: Finnish: mm/yyyy mm/yyyy TOTAL FUNDING £ Theme leads e-signatures: e-signatures: Please return your completed application form to BRC-applications@uhs.nhs.uk, along with the proposed theme lead(s) CV (2-page IRAS format).
Url
/Media/Southampton-Clinical-Research/Downloads/Form-Call-for-EOI-BRC-2028-2035-Candidate-Research-Themes.pdf

ARC SETT project EOI v2 final

Description
Building analytic capability to address compound pressure across health and care systems: testing an approach. Expression of interest: Operational modelling and data science projects In collaboration with Wessex ARC, the SETT Centre is excited to announce an opportunity for innovative operational modelling projects. We are offering data science expertise and support for clinical data extraction to several projects over the next 12 months (expected completion by March 2026). Analysing large-scale data across the health and care system is crucial for addressing key research priorities in Wessex. These priorities include understanding and mitigating pressures on the health and care system. We are keen to develop collaborative partnerships that bring together clinicians, data scientists specialising in operational modelling, and clinical experts. We aim to tackle complex healthcare challenges by uniting these diverse skill sets. Our goal is to address problems that meet three key criteria: they should be relevant to University Hospital Southampton and its patients (UHS), amenable to data modelling tool and techniques and beneficial to the broader healthcare community. Through this approach, we hope to develop innovative solutions that improve local healthcare operations and have the potential to make a wider impact in the field. By leveraging the combined expertise of our collaborators, we can create data-driven insights that lead to more efficient and effective healthcare delivery. Our offer The SETT: Data & AI team will • Provide data science support and advice on data availability and use, to address operational challenges. • Provide UHS clinical data extraction by the Data and AI team to 3-4 projects • Host a future workshop bringing together project teams to share findings. • Data will be shared via the Wessex SDE Project details • Projects to have a clear demonstration of data modelling for service improvement/audit. • Awards are expected to pump prime larger projects, further grant applications or clinical trials within 2-3 years. • Should focus on areas of interest to UHS NHS Foundation Trust – projects that address theatre scheduling and emergency department flow are particularly welcome. • Award is open to all UHS/UoS research leads (The lead investigator will have a substantive or honorary contract with UHS) • Project teams are expected to include both academic and clinical team members, ensuring that skills are shared and learning is translated into operational improvement and, in turn, improved care. • Projects are expected to run for a maximum of 12 months. • Teams are expected to produce a final report and present their work at a SETT-hosted workshop. Key dates • Deadline for applications Friday 14th February • Applications will be considered by the Data Access Committee (DAC) Thursday 13th March • Operational Impact Workshop autumn 2025 (tbc) Please submit this application to SETT via email :- SETT@uhs.nhs.uk by Friday 14th February. Page 1 of 5 Section 1: Application Summary Information a) Lead applicant details: (must hold honorary contract with UHS) Name: Post: Employing organisation: Email: b) Co-applicant details (including academic and clinical members) Name: Post: Employing organisation: Role/contribution to the project: Name: Post: Employing organisation: Role/contribution to the project Name: Post: Employing organisation: Role/contribution to the project c) Project title: d) Proposed start date: e) Project duration in months Page 2 of 5 Section 2 1. Plain English summary of the project – (Word limit 500 max) 2. Project plan and methods to be employed - Background, objectives, design, outcomes. (Word limit 1000 max) 3. Data elements required Page 3 of 5 4. Dissemination and knowledge transfer plan (Word limit 300 max) 5. What impact will this project have and how will it inform a future work programme? (Word limit 300 max) 6. Additional information - Is there any further information that may support your application? Page 4 of 5 Authorisation Lead applicant. Responsibility for overall management and delivery of the project. If awarded the grant you agree to respond to request for data on the progress and impact of the project to enable SETT to meet the requirements of our agreement with Wessex ARC Date of application Send your completed application form and costing template to SETT@uhs.nhs.uk Closing date for submissions Friday 14th February 2025 Page 5 of 5
Url
/Media/Southampton-Clinical-Research/Downloads/ARC-SETT-project-EOI-v2-final.pdf

Whooping cough (pertussis) ADACEL® vaccine in pregnancy (from 16 weeks onwards) - patient information

Description
This factsheet is a guide to having the whooping cough (pertussis) ADACEL® vaccine while you are pregnant (from 16 weeks onwards).
Url
/Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Whooping-cough-pertussis-ADACEL®-vaccine-in-pregnancy-from-16-weeks-onwards-3782-PIL.pdf
161 to 170 of 373
Previous … 15 16 17 18 19 … Next